<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IMR</journal-id>
<journal-id journal-id-type="hwp">spimr</journal-id>
<journal-title>Journal of International Medical Research</journal-title>
<issn pub-type="ppub">0300-0605</issn>
<issn pub-type="epub">1473-2300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300060513476595</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300060513476595</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Notes</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Expression and clinical significance of connective tissue growth factor in thyroid carcinomas</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Guimin</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513476595">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Wei</given-names></name>
<xref ref-type="aff" rid="aff2-0300060513476595">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Meng</surname><given-names>Wei</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513476595">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Jia</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513476595">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Peisong</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513476595">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lin</surname><given-names>Shan</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513476595">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Xu</surname><given-names>Liyan</given-names></name>
<xref ref-type="aff" rid="aff3-0300060513476595">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Enmin</given-names></name>
<xref ref-type="aff" rid="aff3-0300060513476595">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Chen</surname><given-names>Guang</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513476595">1</xref>
<xref ref-type="corresp" rid="corresp1-0300060513476595"/>
</contrib>
</contrib-group>
<aff id="aff1-0300060513476595"><label>1</label>Department of Thyroid Surgery, The First Affiliated Hospital of Jilin University, Changchun, Jilin, China</aff>
<aff id="aff2-0300060513476595"><label>2</label>Department of Breast Surgery, The Second Hospital of Ningbo, Ningbo, Zhejiang, China</aff>
<aff id="aff3-0300060513476595"><label>3</label>Department of Biochemistry and Molecular Biology, Medical College of Shantou University, Shantou, Guangdong, China</aff>
<author-notes>
<corresp id="corresp1-0300060513476595">Dr Guang Chen, Department of Thyroid Surgery, The First Affiliated Hospital, Jilin University, Ziqiang Road, Nanguan Region, Changchun, Jilin, 1320021, China. Email: <email>chenguang518@yahoo.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>4</issue>
<fpage>1214</fpage>
<lpage>1220</lpage>
<history>
<date date-type="received"><day>16</day><month>11</month><year>2012</year></date>
<date date-type="accepted"><day>2</day><month>12</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec10-0300060513476595"><title>Objectives</title>
<p>To examine expression of the connective tissue growth factor (<italic>CTGF</italic>) gene in human thyroid cancer and establish whether a correlation exists between the presence of CTGF protein and clinicopathological parameters of the disease.</p>
</sec>
<sec id="sec11-0300060513476595"><title>Methods</title>
<p>CTGF protein expression was investigated retrospectively by immunohistochemical analysis of CTGF protein levels in thyroid tumour tissue. Associations between immunohistochemical score and several clinicopathological parameters were examined.</p>
</sec>
<sec id="sec12-0300060513476595"><title>Results</title>
<p>In total, 131 thyroid tissue specimens were included. High levels of CTGF protein were observed in papillary thyroid carcinoma tissue; benign thyroid tumour tissue scored negatively for CTGF protein. In papillary thyroid carcinoma, there was a significant relationship between high CTGF protein levels and Union for International Cancer Control disease stage III–IV, and presence of lymph node metastasis. In papillary thyroid carcinomas, CTGF protein levels were not significantly associated with sex or age.</p>
</sec>
<sec id="sec13-0300060513476595"><title>Conclusions</title>
<p>These findings suggest that the CTGF protein level is increased in papillary thyroid carcinoma cells compared with benign thyroid tumours. CTGF expression might play a role in the development of malignant tumours in the thyroid.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Thyroid cancer</kwd>
<kwd>connective tissue growth factor</kwd>
<kwd>CTGF</kwd>
<kwd>immunohistochemistry</kwd>
<kwd>thyroid carcinoma</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0300060513476595" sec-type="intro"><title>Introduction</title>
<p>Thyroid carcinoma is the most common malignancy of the endocrine system and accounts for ∼1% of newly diagnosed cancers.<sup><xref ref-type="bibr" rid="bibr1-0300060513476595">1</xref></sup> Thyroid carcinoma can be divided into papillary, follicular, medullary and anaplastic types.<sup><xref ref-type="bibr" rid="bibr2-0300060513476595">2</xref>,<xref ref-type="bibr" rid="bibr3-0300060513476595">3</xref></sup> Papillary is the most common thyroid carcinoma, accounting for &gt;83% of all such malignancies.<sup><xref ref-type="bibr" rid="bibr4-0300060513476595">4</xref>,<xref ref-type="bibr" rid="bibr5-0300060513476595">5</xref></sup> The prognosis for patients with thyroid malignancy has improved as a result of the standardization of surgical techniques and advances in chemotherapy, although the rates of early diagnosis remain poor.<sup><xref ref-type="bibr" rid="bibr6-0300060513476595">6</xref></sup> An increased understanding of molecular diagnostic features in thyroid cancer may be useful in improving its early diagnosis.</p>
<p>Connective tissue growth factor (CTGF; also known as CCN2), is a member of the CCN protein family. This protein family includes cysteine-rich, angiogenic inducer, 61 (CYR61 or CCN1), nephroblastoma overexpressed (NOV or CCN3), wingless-type mouse mammary tumour virus integration site family member 1 (WNT1) inducible signalling pathway protein 1 (WISP1 or CCN4), WNT1 inducible signaling pathway protein 2 (WISP2 or CCN5) and WNT1 inducible signalling pathway protein 3 (WISP3 or CCN6).<sup><xref ref-type="bibr" rid="bibr7-0300060513476595">7</xref>,<xref ref-type="bibr" rid="bibr8-0300060513476595">8</xref></sup> CNN proteins are involved in numerous cellular processes including proliferation, connection, migration and differentiation, and in broader biological processes including fibrosis, wound healing and carcinogenesis; they are also involved in tumour development and progression.<sup><xref ref-type="bibr" rid="bibr9-0300060513476595">9</xref>,<xref ref-type="bibr" rid="bibr10-0300060513476595">10</xref></sup> One study showed that CTGF protein expression is closely related to the pathological grade of enchondroma, and could play an important role in the assessment of tumour grading and disease prognosis.<sup><xref ref-type="bibr" rid="bibr11-0300060513476595">11</xref></sup> CTGF has been found to induce tumour cell apoptosis in the breast cancer cell line MCF-7.<sup><xref ref-type="bibr" rid="bibr12-0300060513476595">12</xref></sup> In hepatocellular carcinoma and metastatic liver cancer, CTGF protein expression in tumour tissue was significantly higher than in tissue surrounding the tumour.<sup><xref ref-type="bibr" rid="bibr13-0300060513476595">13</xref></sup> However, few studies have reported CTGF protein expression in thyroid carcinomas.<sup><xref ref-type="bibr" rid="bibr14-0300060513476595">14</xref></sup></p>
<p>The present retrospective study examined CTGF protein expression levels in human thyroid carcinomas, using immunohistochemical analysis. Relationships between immunohistochemical scores and several clinicopathological parameters were examined to determine the association between CTGF and thyroid carcinoma.</p>
</sec>
<sec id="sec2-0300060513476595" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0300060513476595"><title>Study population and tissue samples</title>
<p>Tumour specimens were obtained from patients with thyroid tumours who had undergone surgery at the Department of Thyroid Surgery, The First Affiliated Hospital of Jilin University, Changchun, Jilin, China, between January 2006 and March 2009. Case information was retrieved from patients’ medical records. Thyroid cancers were classified according to the fifth edition of the tumour–node–metastasis classification of the Union for International Cancer Control (UICC).<sup><xref ref-type="bibr" rid="bibr15-0300060513476595">15</xref></sup> There were no other specific inclusion or exclusion criteria. Thyroid tissue was removed during surgery, cut into 10–20-µm sections, immediately snap frozen in liquid nitrogen, then stored at −80℃ until use.</p>
<p>Written informed consent was obtained from all patients who participated in this study. The study protocol was reviewed and approved by the Ethics Committee of The First Affiliated Hospital of Jilin University.</p>
</sec>
<sec id="sec4-0300060513476595"><title>Immunohistochemical staining</title>
<p>Frozen thyroid tissue samples were fixed in 4% paraformaldehyde, dehydrated and subjected to routine paraffin-wax embedding and sectioning at 4 µm. For immunohistochemical analysis, sections were deparaffinized with xylene and rehydrated through a graded ethanol series. Antigen retrieval was achieved by boiling the sections for 10 min in 0.01 M citrate buffer (pH 6.0) and endogenous peroxidase was blocked by incubation in 0.3% hydrogen peroxide in methanol for 30 min at room temperature. Nonspecific binding was blocked by incubating slides with normal goat serum for 30 min at room temperature. Sections were incubated overnight at 4℃ with mouse antihuman CTGF primary antibody (1 : 50 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA). After washing three times with 0.01 M phosphate-buffered saline (pH 7.2), sections were incubated with biotin-labelled rabbit antimouse antibody (1 : 200 dilution; ZSGB-BIO, Beijing, China) for 2 h at room temperature. After washing three times with 0.01 M PBS (pH 7.2), immunostaining was visualized using a streptavidin-peroxidase reaction system, then developed with diaminobenzidine-hydrogen peroxide (Wuhan Boster Biological Technology Ltd, Wuhan, China). The degree of immunoreactivity was assessed semiquantitatively, as described previously,<sup><xref ref-type="bibr" rid="bibr16-0300060513476595">16</xref></sup> using a scale from 0 to 3, where 0 represents absolutely no immunostaining, 1 represents &lt;25% immunoreactive cells, 2 represents 25–50% of immunoreactive cells and 3 represents &gt;50% of immunoreactive cells. Values of 0 and 1 indicated negative and low staining scores, respectively; values of 2 and 3 indicated high staining scores.</p>
</sec>
<sec id="sec5-0300060513476595"><title>Statistical analyses</title>
<p>Statistical analyses were performed using the SPSS® software package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows®. Analysis of variance was used to evaluate the difference in CTGT protein levels between different groups. A <italic>P</italic>-value &lt;0.05 was considered to be statistically significant.</p>
</sec>
</sec>
<sec id="sec6-0300060513476595" sec-type="results"><title>Results</title>
<p>Thyroid tissue specimens were obtained from 131 patients undergoing surgery for thyroid tumours (mean ± SD age, 40.2 ± 0.6 years): demographic and clinical characteristics are presented in <xref ref-type="table" rid="table1-0300060513476595">Table 1</xref>. There was no significant difference in terms of tumour type, patient age or sex.
<table-wrap id="table1-0300060513476595" position="float"><label>Table 1.</label><caption><p>Demographic and clinical data for patients undergoing surgery for thyroid tumours.</p></caption>
<graphic alternate-form-of="table1-0300060513476595" xlink:href="10.1177_0300060513476595-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Characteristic</th>
<th rowspan="2">Parameter</th>
<th colspan="4">Incidence</th>
</tr>
<tr><th>Total thyroid neoplasms <italic>n</italic> = 131</th>
<th>Benign thyroid tumours <italic>n</italic> = 13</th>
<th>Thyroid carcinoma <italic>n</italic> = 118</th>
<th>Papillary thyroid carcinoma <italic>n</italic> = 109</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Sex</td>
<td>Male</td>
<td>29 (22.1)</td>
<td>5 (38.5)</td>
<td>24 (20.3)</td>
<td>23 (21.1)</td>
</tr>
<tr>
<td>Female</td>
<td>102 (77.9)</td>
<td>8 (61.5)</td>
<td>94 (79.7)</td>
<td>86 (78.9)</td>
</tr>
<tr>
<td>Age, years</td>
<td>&lt;45</td>
<td>68 (51.9)</td>
<td>5 (38.5)</td>
<td>63 (53.4)</td>
<td>61 (56.0)</td>
</tr>
<tr>
<td>≥45</td>
<td>63 (48.1)</td>
<td>8 (61.5)</td>
<td>55 (46.6)</td>
<td>48 (44.0)</td>
</tr>
<tr>
<td>Histological type</td>
<td>Nodular goitre</td>
<td>NA</td>
<td>3 (23.1)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Thyroid adenoma</td>
<td>NA</td>
<td>7 (53.9)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Nodular goitre with adenoma</td>
<td>NA</td>
<td>3 (23.1)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Papillary</td>
<td>NA</td>
<td>NA</td>
<td>109 (92.4)</td>
<td>NA</td>
</tr>
<tr>
<td>Follicular</td>
<td>NA</td>
<td>NA</td>
<td>5 (4.2)</td>
<td>NA</td>
</tr>
<tr>
<td>Medullary</td>
<td>NA</td>
<td>NA</td>
<td>4 (3.4)</td>
<td>NA</td>
</tr>
<tr>
<td>Regional lymph nodes</td>
<td>N0</td>
<td>NA</td>
<td>NA</td>
<td>75 (63.6)</td>
<td>68 (62.4)</td>
</tr>
<tr>
<td>N1</td>
<td>NA</td>
<td>NA</td>
<td>43 (36.4)</td>
<td>41 (37.6)</td>
</tr>
<tr>
<td>UICC stage</td>
<td>I–II</td>
<td>NA</td>
<td>NA</td>
<td>99 (83.9)</td>
<td>92 (84.4)</td>
</tr>
<tr>
<td>III–IV</td>
<td>NA</td>
<td>NA</td>
<td>19 (16.1)</td>
<td>17 (15.6)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0300060513476595">
<p>Data presented as <italic>n</italic> (%) of patients.</p></fn>
<fn id="table-fn2-0300060513476595">
<p>N0, tumour cells absent from regional lymph nodes; N1, regional lymph node metastasis present; UICC stage, Union for International Cancer Control tumour–node–metastasis classification.<sup><xref ref-type="bibr" rid="bibr15-0300060513476595">15</xref></sup></p></fn></table-wrap-foot>
</table-wrap></p>
<p>Immunoreactivity to CTGF appeared as fine, granular to diffuse, cytoplasmic and membrane staining (<xref ref-type="fig" rid="fig1-0300060513476595">Figure 1</xref>). The expression of CTGF protein varied among the different thyroid tumour types (<xref ref-type="table" rid="table2-0300060513476595">Table 2</xref>). Benign thyroid tumours (nodular goitre, adenoma, nodular goitre with adenoma) were nonreactive (negative) for CTGF. For thyroid cancers (papillary, follicular and medullary), both low and high CTGF scores were observed, with no cases scoring negatively. There was a significant difference in CTGF protein expression between malignant and benign thyroid tumours (<xref ref-type="table" rid="table2-0300060513476595">Table 2</xref>; <italic>P</italic> = 0.004).
<fig id="fig1-0300060513476595" position="float"><label>Figure 1.</label><caption><p>Immunohistochemical staining for connective tissue growth factor in malignant and benign tumour tissue sections from patients undergoing surgery for thyroid tumours: (A) nodular goitre; (B) thyroid adenoma; (C) papillary thyroid carcinoma; (D) follicular thyroid carcinoma; (E) medullary thyroid carcinoma.</p></caption><graphic xlink:href="10.1177_0300060513476595-fig1.tif"/>
</fig>
<table-wrap id="table2-0300060513476595" position="float"><label>Table 2.</label><caption><p>Connective tissue growth factor protein expression in thyroid carcinoma and benign thyroid tumour tissue samples from patients undergoing surgery for thyroid tumours.</p></caption>
<graphic alternate-form-of="table2-0300060513476595" xlink:href="10.1177_0300060513476595-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Tumour histological type</th>
<th>CTGF score 0–1</th>
<th>CTGF score 2–3</th>
<th>Statistical significance<sup><xref ref-type="table-fn" rid="table-fn4-0300060513476595">a</xref></sup></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Papillary, <italic>n</italic> = 109</td>
<td>63 (57.8)</td>
<td>46 (42.2)</td>
<td rowspan="6"><italic>P</italic> = 0.004</td>
</tr>
<tr>
<td>Follicular, <italic>n</italic> = 5</td>
<td>4 (80.0)</td>
<td>1 (20.0)</td>
</tr>
<tr>
<td>Medullary, <italic>n</italic> = 4</td>
<td>4 (100)</td>
<td>–</td>
</tr>
<tr>
<td>Nodular goitre, <italic>n</italic> = 3</td>
<td>3 (100)–</td>
<td>–</td>
</tr>
<tr>
<td>Thyroid adenoma, <italic>n</italic> = 7</td>
<td>7 (100–</td>
<td>–</td>
</tr>
<tr>
<td>Nodular goitre with adenoma, <italic>n</italic> = 3</td>
<td>3 (100)–</td>
<td>–</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0300060513476595">
<p>Data presented as <italic>n</italic> (%) patient incidence.</p></fn>
<fn id="table-fn4-0300060513476595"><label>a</label><p>Thyroid carcinoma types versus benign thyroid tumour types; analysis of variance.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>High CTGF staining was significantly associated with lymph node metastasis and UICC stage (<italic>P</italic> &lt; 0.001, <xref ref-type="table" rid="table3-0300060513476595">Table 3</xref>). No relationship was observed between CTGF immunoreactivity and sex or age in papillary thyroid carcinoma (<xref ref-type="table" rid="table3-0300060513476595">Table 3</xref>).
<table-wrap id="table3-0300060513476595" position="float"><label>Table 3.</label><caption><p>Relationship between intensity of connective tissue growth factor staining and clinicopathological characteristics, in papillary thyroid carcinoma tissue samples from patients (<italic>n</italic> = 109) undergoing surgery for thyroid tumours.</p></caption>
<graphic alternate-form-of="table3-0300060513476595" xlink:href="10.1177_0300060513476595-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th>Parameter</th>
<th>CTGF score 0–1</th>
<th>CTGF score 2–3</th>
<th>Statistical significance</th>
</tr></thead>
<tbody align="left">
<tr>
<td rowspan="2">Sex</td>
<td>Male, <italic>n</italic> = 23</td>
<td>10 (43.5)</td>
<td>13 (56.5)</td>
<td rowspan="2">NS</td>
</tr>
<tr>
<td>Female, <italic>n</italic> = 86</td>
<td>53 (61.6)</td>
<td>33 (38.4)</td>
</tr>
<tr>
<td rowspan="2">Age, years</td>
<td>&lt;45, <italic>n</italic> = 61</td>
<td>34 (55.7)</td>
<td>27 (44.3)</td>
<td rowspan="2">NS</td>
</tr>
<tr>
<td>≥45, <italic>n</italic> = 48</td>
<td>29 (60.4)</td>
<td>19 (39.6)</td>
</tr>
<tr>
<td rowspan="2">Regional lymph nodes</td>
<td>N0, <italic>n</italic> = 68</td>
<td>53 (77.9)</td>
<td>15 (22.1)</td>
<td rowspan="2"><italic>P</italic> &lt; 0.001<sup><xref ref-type="table-fn" rid="table-fn6-0300060513476595">a</xref></sup></td>
</tr>
<tr>
<td>N1, <italic>n</italic> = 41</td>
<td>10 (24.4)</td>
<td>31 (75.6)</td>
</tr>
<tr>
<td rowspan="2">UICC stage</td>
<td>I–II, <italic>n</italic> = 92</td>
<td>60 (65.2)</td>
<td>32 (34.8)</td>
<td rowspan="2"><italic>P</italic> &lt; 0.001<sup>b</sup></td>
</tr>
<tr>
<td>III–IV, <italic>n</italic> = 17</td>
<td>3 (17.6)</td>
<td>14 (82.4)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0300060513476595">
<p>Data presented as <italic>n</italic> (%) patient incidence.</p></fn>
<fn id="table-fn6-0300060513476595"><label>a</label><p>N0 versus N1; <sup>b</sup>UICC stage I – II versus UICC stage III – IV; analysis of variance.</p></fn>
<fn id="table-fn7-0300060513476595">
<p>NS, no statistically significant differences (<italic>P</italic> ≥ 0.05); N0, tumour cells absent from regional lymph nodes; N1, regional lymph node metastasis present; UICC stage, Union for International Cancer Control tumour–node–metastasis classification.<sup><xref ref-type="bibr" rid="bibr15-0300060513476595">15</xref></sup></p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec7-0300060513476595" sec-type="discussion"><title>Discussion</title>
<p>Connective tissue growth factor is believed to be a multifunctional signaling modulator that is involved in a variety of biological or pathological processes such as angiogenesis, osteogenesis, fibrosis in the kidneys and skin, and tumour development.<sup><xref ref-type="bibr" rid="bibr17-0300060513476595">17</xref><xref ref-type="bibr" rid="bibr18-0300060513476595"/>–<xref ref-type="bibr" rid="bibr19-0300060513476595">19</xref></sup> <italic>CTGF</italic> has been identified as an oncogene in a number of cancer types. <sup><xref ref-type="bibr" rid="bibr12-0300060513476595">12</xref>,<xref ref-type="bibr" rid="bibr20-0300060513476595">20</xref><xref ref-type="bibr" rid="bibr21-0300060513476595"/><xref ref-type="bibr" rid="bibr22-0300060513476595"/>–<xref ref-type="bibr" rid="bibr23-0300060513476595">23</xref></sup> The <italic>CTGF</italic> gene is overexpressed in prostate cancer,<sup><xref ref-type="bibr" rid="bibr20-0300060513476595">20</xref></sup> glioma,<sup><xref ref-type="bibr" rid="bibr21-0300060513476595">21</xref></sup> breast cancer<sup><xref ref-type="bibr" rid="bibr12-0300060513476595">12</xref></sup> and adult acute lymphoblastic leukaemia.<sup><xref ref-type="bibr" rid="bibr22-0300060513476595">22</xref></sup> Increased CTGF protein expression is also associated with progression of cervical tumours<sup><xref ref-type="bibr" rid="bibr23-0300060513476595">23</xref></sup> and oesophageal squamous cell carcinoma.<sup><xref ref-type="bibr" rid="bibr24-0300060513476595">24</xref></sup> Conversely, in lung adenocarcinoma<sup><xref ref-type="bibr" rid="bibr25-0300060513476595">25</xref></sup> and colorectal cancer,<sup><xref ref-type="bibr" rid="bibr26-0300060513476595">26</xref></sup> overexpression of the <italic>CTGF</italic> gene inhibits invasion and metastasis of cancer cells, both <italic>in vitro</italic> and <italic>in vivo</italic>.</p>
<p>Although specific criteria are used to diagnose various thyroid neoplasms, it can be difficult to distinguish between carcinomas (such as papillary carcinomas) and adenomas.<sup><xref ref-type="bibr" rid="bibr3-0300060513476595">3</xref>,<xref ref-type="bibr" rid="bibr4-0300060513476595">4</xref></sup> Thyroid cancer-related molecular diagnostic features that could assist in this distinction would have great clinical value. The present study demonstrated that CTGF protein expression differed significantly between benign thyroid tumours and thyroid carcinomas. All 13 cases of benign thyroid tumours were negative for CTGF. In papillary thyroid carcinoma, 63 cases showed low CTGF scores and 46 showed high CTGF scores. Moreover, four cases of follicular thyroid carcinoma and four cases of medullary thyroid carcinoma showed low CTGF scores. These data suggest that the level of CTGF protein expression may have clinical significance in the differential diagnosis of benign versus malignant thyroid tumours.</p>
<p>In conclusion, the present study demonstrated that CTGF protein expression was significantly upregulated in thyroid carcinoma tissue compared with benign thyroid tumour tissue, suggesting that CTGF may be involved in the development of malignant thyroid tumours. The number of patients studied was, however, relatively small. Further research, involving a larger number of patients, is needed in order to verify these findings.</p>
</sec>
</body>
<back>
<sec id="sec8-0300060513476595"><title>Declaration of conflicting interest</title>
<p>The authors declare that there are no conflicts of interest.</p>
</sec>
<sec id="sec9-0300060513476595"><title>Funding</title>
<p>The authors gratefully acknowledge the financial support provided by The Health Bureau of Jilin, grant No. 2008Z017.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-0300060513476595"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nikiforova</surname><given-names>MN</given-names></name><name><surname>Nikiforov</surname><given-names>YE</given-names></name></person-group>. <article-title>Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis</article-title>. <source>Expert Rev Mol Diagn</source> <year>2008</year>; <volume>8</volume>: <fpage>83</fpage>–<lpage>95</lpage>.</citation></ref>
<ref id="bibr2-0300060513476595"><label>2</label><citation citation-type="book"><person-group person-group-type="editor"><name><surname>DeLellis</surname><given-names>RA</given-names></name><name><surname>Lloyd</surname><given-names>RV</given-names></name><name><surname>Heitz</surname><given-names>PU</given-names></name><etal/></person-group>. <source>World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of Endocrine Organs</source>, <publisher-loc>Lyon</publisher-loc>: <publisher-name>IARC Press</publisher-name>, <year>2004</year>.</citation></ref>
<ref id="bibr3-0300060513476595"><label>3</label><citation citation-type="book"><person-group person-group-type="editor"><name><surname>Nikiforov</surname><given-names>YE</given-names></name></person-group>. <source>Diagnostic Pathology and Molecular Genetics of the Thyroid: A Comprehensive Guide for Practicing Thyroid Pathology</source>, <edition>2nd ed</edition>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>, <year>2012</year>.</citation></ref>
<ref id="bibr4-0300060513476595"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>RL</given-names></name><name><surname>de Souza</surname><given-names>JA</given-names></name><name><surname>Cohen</surname><given-names>EE</given-names></name></person-group>. <article-title>Thyroid cancer: burden of illness and management of disease</article-title>. <source>J Cancer</source> <year>2011</year>; <volume>2</volume>: <fpage>193</fpage>–<lpage>199</lpage>.</citation></ref>
<ref id="bibr5-0300060513476595"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dal Maso</surname><given-names>L</given-names></name><name><surname>Bosetti</surname><given-names>C</given-names></name><name><surname>La Vecchia</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors</article-title>. <source>Cancer Causes Control</source> <year>2009</year>; <volume>20</volume>: <fpage>75</fpage>–<lpage>86</lpage>.</citation></ref>
<ref id="bibr6-0300060513476595"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>SI</given-names></name></person-group>. <article-title>Thyroid carcinoma</article-title>. <source>Lancet</source> <year>2003</year>; <volume>361</volume>: <fpage>501</fpage>–<lpage>511</lpage>.</citation></ref>
<ref id="bibr7-0300060513476595"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>LF</given-names></name><name><surname>Lam</surname><given-names>SC</given-names></name></person-group>. <article-title>The CCN family of angiogenic regulators: the integrin connection</article-title>. <source>Exp Cell Res</source> <year>1999</year>; <volume>248</volume>: <fpage>44</fpage>–<lpage>57</lpage>.</citation></ref>
<ref id="bibr8-0300060513476595"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>W</given-names></name><name><surname>Yin</surname><given-names>D</given-names></name><name><surname>Gui</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells</article-title>. <source>Mol Cancer Res</source> <year>2006</year>; <volume>4</volume>: <fpage>591</fpage>–<lpage>598</lpage>.</citation></ref>
<ref id="bibr9-0300060513476595"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gery</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>D</given-names></name><name><surname>Yin</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells</article-title>. <source>Clin Cancer Res</source> <year>2005</year>; <volume>11</volume>: <fpage>7243</fpage>–<lpage>7254</lpage>.</citation></ref>
<ref id="bibr10-0300060513476595"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schober</surname><given-names>JM</given-names></name><name><surname>Lau</surname><given-names>LF</given-names></name><name><surname>Ugarova</surname><given-names>TP</given-names></name><etal/></person-group>. <article-title>Identification of a novel integrin <italic>α</italic><sub>M</sub><italic>β</italic><sub>2</sub> binding site in CCN1 (CYR61), a matricellular protein expressed in healing wounds and atherosclerotic lesions</article-title>. <source>J Biol Chem</source> <year>2003</year>; <volume>278</volume>: <fpage>25808</fpage>–<lpage>25815</lpage>.</citation></ref>
<ref id="bibr11-0300060513476595"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shakunaga</surname><given-names>T</given-names></name><name><surname>Ozaki</surname><given-names>T</given-names></name><name><surname>Ohara</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Expression of connective tissue growth factor in cartilaginous tumors</article-title>. <source>Cancer</source> <year>2000</year>; <volume>89</volume>: <fpage>1466</fpage>–<lpage>1473</lpage>.</citation></ref>
<ref id="bibr12-0300060513476595"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>W</given-names></name><name><surname>O’Kelly</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis</article-title>. <source>Int J Oncol</source> <year>2011</year>; <volume>38</volume>: <fpage>1741</fpage>–<lpage>1747</lpage>.</citation></ref>
<ref id="bibr13-0300060513476595"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirasaki</surname><given-names>S</given-names></name><name><surname>Koide</surname><given-names>N</given-names></name><name><surname>Ujike</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Expression of Nov, CYR61 and CTGF genes in human hepatocellular carcinoma</article-title>. <source>Hepatol Res</source> <year>2001</year>; <volume>19</volume>: <fpage>294</fpage>–<lpage>305</lpage>.</citation></ref>
<ref id="bibr14-0300060513476595"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Mao</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>CTGF is overexpressed in papillary thyroid carcinoma and promotes the growth of papillary thyroid cancer cells</article-title>. <source>Tumour Biol</source> <year>2011</year>; <volume>32</volume>: <fpage>721</fpage>–<lpage>728</lpage>.</citation></ref>
<ref id="bibr15-0300060513476595"><label>15</label><citation citation-type="other"><comment>Sobin LH, Wittekind C, International Union against Cancer (eds). <italic>TNM Classification of Malignant Tumors</italic>. 5th ed. New York: John Wiley &amp; Sons, 1997</comment>.</citation></ref>
<ref id="bibr16-0300060513476595"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Merino</surname><given-names>MJ</given-names></name><name><surname>Liotta</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue</article-title>. <source>Hum Pathol</source> <year>1992</year>; <volume>23</volume>: <fpage>1395</fpage>–<lpage>1401</lpage>.</citation></ref>
<ref id="bibr17-0300060513476595"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perbal</surname><given-names>B</given-names></name></person-group>. <article-title>NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues</article-title>. <source>Mol Pathol</source> <year>2001</year>; <volume>54</volume>: <fpage>57</fpage>–<lpage>79</lpage>.</citation></ref>
<ref id="bibr18-0300060513476595"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brigstock</surname><given-names>DR</given-names></name></person-group>. <article-title>The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family</article-title>. <source>Endocr Rev</source> <year>1999</year>; <volume>20</volume>: <fpage>189</fpage>–<lpage>206</lpage>.</citation></ref>
<ref id="bibr19-0300060513476595"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>MH</given-names></name><name><surname>Sanchez</surname><given-names>T</given-names></name><name><surname>Pappalardo</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Induction of antiproliferative connective tissue growth factor expression in Wilms’ tumor cells by sphingosine-1-phosphate receptor 2</article-title>. <source>Mol Cancer Res</source> <year>2008</year>; <volume>6</volume>: <fpage>1649</fpage>–<lpage>1656</lpage>.</citation></ref>
<ref id="bibr20-0300060513476595"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Tuxhorn</surname><given-names>JA</given-names></name><name><surname>Ressler</surname><given-names>SJ</given-names></name><etal/></person-group>. <article-title>Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis</article-title>. <source>Cancer Res</source> <year>2005</year>; <volume>65</volume>: <fpage>8887</fpage>–<lpage>8895</lpage>.</citation></ref>
<ref id="bibr21-0300060513476595"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>D</given-names></name><name><surname>Yin</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Levels of expression of <italic>CYR61</italic> and <italic>CTGF</italic> are prognostic for tumor progression and survival of individuals with gliomas</article-title>. <source>Clin Cancer Res</source> <year>2004</year>; <volume>10</volume>: <fpage>2072</fpage>–<lpage>2081</lpage>.</citation></ref>
<ref id="bibr22-0300060513476595"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sala-Torra</surname><given-names>O</given-names></name><name><surname>Gundacker</surname><given-names>HM</given-names></name><name><surname>Stirewalt</surname><given-names>DL</given-names></name><etal/></person-group>. <article-title>Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia</article-title>. <source>Blood</source> <year>2007</year>; <volume>109</volume>: <fpage>3080</fpage>–<lpage>3083</lpage>.</citation></ref>
<ref id="bibr23-0300060513476595"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>YF</given-names></name><name><surname>Cheung</surname><given-names>TH</given-names></name><name><surname>Tsao</surname><given-names>GS</given-names></name><etal/></person-group>. <article-title>Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray</article-title>. <source>Int J Cancer</source> <year>2006</year>; <volume>118</volume>: <fpage>2461</fpage>–<lpage>2469</lpage>.</citation></ref>
<ref id="bibr24-0300060513476595"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>YZ</given-names></name><name><surname>Chen</surname><given-names>PP</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through <italic>β</italic>-catenin-T-cell factor/Lef signaling</article-title>. <source>J Biol Chem</source> <year>2007</year>; <volume>282</volume>: <fpage>36571</fpage>–<lpage>36581</lpage>.</citation></ref>
<ref id="bibr25-0300060513476595"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Shih</surname><given-names>JY</given-names></name><name><surname>Jeng</surname><given-names>YM</given-names></name><etal/></person-group>. <article-title>Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis</article-title>. <source>J Natl Cancer Inst</source> <year>2004</year>; <volume>96</volume>: <fpage>364</fpage>–<lpage>375</lpage>.</citation></ref>
<ref id="bibr26-0300060513476595"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>BR</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Che</surname><given-names>TF</given-names></name><etal/></person-group>. <article-title>Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer</article-title>. <source>Gastroenterology</source> <year>2005</year>; <volume>128</volume>: <fpage>9</fpage>–<lpage>23</lpage>.</citation></ref>
</ref-list>
</back>
</article>